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Abstract : Genetic alterations in protooncogenes or tumour suppressor genes are
believed to be one of the key events in the
multistage process of carcinogenesis.
Activating point mutations occurring in either
one of the three ras proto-oncogene families
are common genetic alterations in human and
animal neoplasms. However, the mechanisms
leading to oral cancer are not completely
understood. Activation of the ras oncogene in
oral carcinogenesis, although absent or rare in
the western world, accounts for up to 35% of
all malignancies in India and South Asia.
Recognised aetiological agents of oral cancer
include tobacco and alcohol. Tobaccoassociated compounds such as nitrosamines
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Introduction
An increasing amount of evidence suggests that the
multiple genetic events leading to carcinogenesis include
the activation of oncogenes and inactivation of tumour
suppressor genes. Oral carcinogenesis appears to be a
complex phenomenon in which genetic events within
signal trunsduction pathways governing normal cellular
physiology are quantitatively or qualitatively altered (1).
Cytogenic analyses have also shown that structural
abnormalities often involve chromosomes 1, 3 (2, 3), 9
(4), and particularly 11 (5, 6), 13 and 14 (6) in oral
carcinomas. It is possible that these abnormalities may
affect genes involved in carcinogenesis such as oncogenes
and tumour suppressors as well as genes controlling DNA
repair or stability (7). It is also significant that viruses,
most notably the human papilloma virus, have been
associated with oral carcinogenesis (8).
Proto-oncogenes are genes that are present in normal
cells, controlling cell growth, proliferation and
differentiation. The ras gene is one of the most commonly
detected mutated oncogenes in human cancers. The

are linked with carcinogenesis in humans. In
the present paper, point mutations of ras
genes were analysed in human oral cancers.
DNA obtained from the tissue was amplified
by polymerase chain reaction and then
analysed by direct DNA sequencing in order to
detect possible mutations at codons 12, 13
and 61 of H-ras, K-ras and N-ras. The DNA
sequencing analyses revealed that there were
no mutations at the hotspots of the three ras
genes. These results indicate that ras gene
mutation may not play an important role in
the development of oral tumours in western
samples.
Key Words: Oral tumour, PCR, Direct
sequencing, Tobacco-specific nitrosamines

family of ras genes includes three well characterised
genes, H-ras, K-ras and N-ras. All these three genes
contain 4 coding exons that code for highly related
proteins known as 21Kd proteins, which are composed of
188 or 189 amino acids. These genes are converted into
active oncogenes by point mutations at one of the critical
positions of 12, 13 or 61 (9).
Activation of ras genes by point mutations has been
determined in a wide variety of human tumours. It has
also been shown that the frequency of ras gene point
mutations varies in different tumour types. Although
there is a higher frequency of mutations in specific types
of tumours, i.e., in 75-90% of pancreatic
adenocarcinomas (10), 40-50% of colorectal carcinomas
(11, 12), 30% of lung adenocarcinomas (13) and about
25% of acute myeloid leukaemias (14), the overall
incidence of point mutations in ras genes in human
tumours may be only about 10% (15). These point
mutations are very rarely present in renal
adenocarcinomas or in breast cancer, while there is lower
prevalence in thyroid, testicular, skin, bladder,
endometrial and liver cancers (16, 17).
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Different results have been obtained in the study of
mutational activation of the ras oncogene in oral
carcinogenesis. In India (18) and Taiwan (19), ras gene
activation has often been found in oral cancer patients,
whereas studies in Caucasian populations have shown
that ras gene activation is very rare (20-22).
Epidemiological studies have demonstrated that the high
incidence of oral cancer in India and Taiwan is closely
associated with the habit of chewing tobacco or betel quid
(19).
The most important risk factors for oral carcinomas
remain tobacco and alcohol (23). Tobacco smoke contains
more than 4000 compounds, of which at least 50 are
carcinogenic (24). The major inducer of tobacco
dependence for smokers and for tobacco chewers is
nicotine. Cigarette smoking is a worldwide problem.
Moreover, while cigarette smoking levels have declined
during the past 20 years, the production and
consumption of smokeless tobacco products, snuff and
chewing tobacco, has increased significantly (25).
Chemical carcinogens may play an important role in
inducing the ras oncogene in a variety of carcinogeninduced tumours in animal experiments. The ras
oncogene activation that is observed in these experiments
is carcinogen specific and suggests that ras oncogene
activation by carcinogens plays an important role in
chemical carcinogenesis (26). The complex nature of
cigarette smoke precludes the assignment of its
carcinogenic activities to any one compound or group of
compounds. Among the well-established carcinogens
found in tobacco products are tobacco-specific
nitrosamines (TSNA), which chiefly consist of Nnitrosonornicotine (NNN) and 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone (NNK) (27). The comparatively
high concentrations of this group of compounds in
tobacco make them prime candidates for explaining the
carcinogenic activities of tobacco in smokers, snuff
dippers and tobacco chewers.
In this study, we investigated the possible role of ras
oncogene activation in oral cancer patients associated
with tobacco smoking in the UK. The polymerase chain
reaction followed by direct DNA sequencing methods was
used for the analysis of the exon 1 and 2 regions of Hras, K-ras and N-ras genes. The different form or mode
of application of tobacco products was examined in order
to explain the different prevalence of ras gene mutations
in oral carcinogenesis in western and Asian samples.
218

Materials and Methods
Tumour Specimens
Human oral tumour specimens were obtained from
patients undergoing surgery for the removal of oral
squamous cell carcinomas by the West Glamorgan Health
Service. Patient information is given in Table 1. DNA from
placenta was used as the control. The tumour specimens
were frozen and stored at -70ºC until DNA extraction.
DNA was extracted by the phenol/chloroform method and
was then quantitated by UV absorption.

Table 1.

Smoking habits of patients analysed.

Patient number

Age

Sex

8
9
11
12
15
16
18
21
26
34
35
42
44
45
47
51
52
53
55
56
57
59

49
57
48
73
50
61
64
50
81
85
24
70
54
39
57
66
48
67
68
78
82
79

M
M
M
F
F
M
F
F
M
F
F
M
M
M
F
M
M
M
M
F
M
M

Smoking history*
>30/day
>30/day
>30/day
11-20/day
Ex (1)
Ex (12)
Ex (10)
11-20/day
>30/day
non
non
Ex (5)
10/day
non
25/day
Ex (8)
<10/day
non
>30/day
15/day
non
non

* For ex-smokers, years since cessation is in brackets.

Polymerase Chain Reaction
Oligonucleotide sequences were designed to amplify
sequences around either codons 12 and 13 or codon 61
of the H-ras, N-ras and K-ras genes (Table 2). The
selected oligomers (5’-biotin labelled) were synthesized
on an automated DNA synthesizer (Applied Biosystems,
Model 391) as instructed by the manufacturer, using
standard cyanoethylphosphoramidite chemistry.
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Table 2.

Synthetic oligonucleotide sequences used as primers for
human ras gene.

Gene

Priming region

Primer sequences (5’ - 3’)

K-ras

Exon 1

TGACTGAATATAAACTTGTG

(sense)

(codon 12/13)

TATTGTTGGATCATATTCGT

(antisense)

Exon 2

TTCCTACAGGAAGCAAGTAG

(codon 61)

CACAAAGAAAGCCCTCCCCA

Exon 1

GGCAGGAGACCCTGTAGGAG

H-ras

N-ras

(codon 12/13)

GTATTCGTCCACAAAATGGTTCT

Exon 2

CTACCGGAAGCAGGTGGTCATT

(codon 61)

CGCATGTACTGGTCCCGCAT

Exon 1

GACTGAGTACAAACTGGTGG

(codon 12/13)

CTCTATGGTGGGATCATATT

Exon 2

TCTTACAGAAAACAAGTGGT

(codon 61)

ATACACAGAGGAAGCCTTCG

PCR was performed with 10 µl (1µg) of genomic DNA
solution, 40 pmol of each primer, 200 µM of
deoxynucleotide triphosphates, 10 X PCR buffer (100
mM Tris-HCl, pH 8.8; 15 mM MgCl2; 500 mM KCl; 1%
Triton X-100) and 2.5 U Taq polymerase in a final
volume of 100 µl. The samples were overlaid with 70 µl
mineral oil and subjected to cycles of PCR amplification
using the Hybaid Omnigene HB-IR-CM DNA amplification
machine occording to the following thermocycling
protocol: initial denaturation at 94ºC for 2 minutes,
followed by 30-35 cycles at 94ºC for 1 minute, annealing
for 30 seconds and extension at 72ºC for 30 seconds.
Table 3 shows the optimum annealing temperatures and
cycle numbers for each gene region.
Table 3.
Gene region

PCR parameters for ras gene primers.
Annealing
Temperature

Cycle
number

Product
length (bp)

K-ras
Exon 1
Exon 2

55
60

35
35

107
128

H-ras
Exon 1
Exon 2

56
59

35
30

145
102

N-ras
Exon 1
Exon 2

59
59

30
35

109
130

After amplification, the DNA was resolved by
electrophoresis in 6% of acrylamide gel and stained with
silver nitrate to ensure the presence of 102 to 145 baseamplified DNA.
Direct Sequencing Method
Streptavidin coated magnetic beads (Dynabeads M280, Dynal) were used as solid support in the purification
and isolation of the single-stranded DNA of PCR products.
The immobilised single-stranded DNA was sequenced
using a Sequenase Version 2.0 DNA Sequencing Kit
(United States Biochemicals) according to the
dideoxynucleotide chain termination method (28)
The sequencing reaction protocols were as follows: 2
µl of 5 X reaction buffer (200 mM Tris-HCl, pH 7.5; 250
mM NaCl) and 1 µl primer (2 pmol) were mixed in an
Eppendorf tube with 7 µl single-stranded DNA. This
mixture was incubated for two minutes at 65ºC using a
water bath for annealing of the appropriate primer to the
template DNA. The tube was cooled slowly to 35ºC over
15-30 minutes and the annealed template was placed on
ice.
1 ml dithiothreitol (0.1 M DTT), 2 µl of diluted
labelling mix, 0.5 µl of [35S ] dATP (10 ci/ul), 1 µl
manganase buffer (0.1 M MnCl2, 0.15 M sodium
isocitrate) and 2 µl diluted sequenase polymerase were
added to the ice-cold annealed DNA mixture and
incubated at room temperature for 2-5 minutes. Then
this mixture was divided into four tubes containing 2.5 µl
of dideoxy A, C, G and T termination mixtures from the
Sequanase Kit. After incubation at 37ºC for 5 min, 4 µl of
the stop solution (95% formamide, 20 mM EDTA,
0.05% bromophenolblue, 0.05% xylene cyanol FF) was
added to the four individual reaction tubes. These
samples were heated at 85ºC for 2 min and then
subjected to electrophoresis on 8 M urea/6% acrylamide
sequence gel. The gel was dried and exposed to hypaper35
S sequencing film (Amersham) for 48 h.

Results
A total of 22 human oral tumour samples were
examined by PCR and sequencing. In vitro amplification
of the DNA by PCR followed by direct DNA sequencing
methods were used for the analysis of possible mutations
at codons 12, 13 or 61 of the H-ras, K-ras and N-ras
genes.
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PCRs of the tumour samples DNA were used to
generate 107 bp and 128 bp fragments of the K-ras gene
of exons 1 and 2, respectively. Similarly, 145 bp and 102
bp fragments, and 109 bp and 130 bp fragments were
amplified for the H-ras gene and N-ras gene of exons 1
and 2, respectively. The PCR products were resolved on
6% polyacrylamide gels and visualized by silver staining.
Approximately 70 to 100 nucleotides around
individual targeted genes were analyzed by the direct
sequencing method. The analyzed nucleotide sequences of
the tumour samples were in complete agreement with
published nucleotide sequences of H-ras, K-ras and N-ras
genes determined by conventional cloning and sequencing
methods (29-31).
Point mutation analyses of codons 12, 13 and 61 of
the three ras genes were performed on the 22 human
oral tumour samples. Direct DNA sequencing analyses
revealed that no mutations were present at codons 12,
13 and 61 of the H-ras, K-ras and N-ras genes in the DNA
extracted from oral tumours.

Discussion
In this study, we used the sensitive technique of in
vitro enzymatic amplification of target DNA sequences
followed by direct DNA sequence analysis to study point
mutations in ras genes in tobacco-smoking-related
malignancies. PCR and direct sequencing were chosen as
the methods for investigating ras genes mutations
because dot blotting for point mutations is not as
informative as direct sequencing. This method enabled
the sequencing of virtually every nucleotide of the
targeted ras genes. Thus, the results may be considered
accurate and reliable, unlike those of the conventional
cloning and sequencing methods, which take weeks to
complete. The analysis of one oral tumour sample alone
can take a couple of days with these methods.
We have extended (the whole ras gene family) and
confirmed the observations of previous investigators (2022) using direct DNA sequencing to show that mutations
in the ras gene family are extremely rare or are absent in
the pathogenesis of oral cancer in Caucasian patients. No
mutations were observed in the H-ras, K-ras and N-ras
genes in the 22 oral tumour samples. Our results and
those of other investigators suggest that ras mutations
are infrequent in western samples in contrast to the
findings of some studies which were carried out on Indian
220

and Taiwanese oral cancer patients. Saranath et al. (18)
reported that a significantly high proportion of oral
cancer patients (35%) have point mutations in codons
12, 13 or 61 of the H-ras gene in Indian patients.
Mutations in primary tumours of the oral cavity from an
eastern Indian population were observed in H-ras and Kras genes at a frequency of 28% and 33%, respectively
(32). H-ras oncogene activations have also been found at
codon 59 in Indian oral cancer patients (33). Point
mutations in K-ras codon 12 have also been reported in
tumour samples obtained from Taiwan by Kuo et al. (19).
In these studies, samples were collected from patients
who had habitually chewed tobacco and betel quid
together. Thus, the possible reason for the absence or
low frequency of ras gene mutations in the development
of oral cancer in western populations might be the
differences in the mode of exposure to tobacco and
tobacco products. This difference between smoking and
chewing tobacco should be taken into consideration when
explaining the occurrence of ras gene mutations in India
and Taiwan.
In addition to tobacco, other principal risk factors,
have been proposed. These are the patients’ diet and the
intake of certain nutrients such as iron and vitamin C,
dental status and the patients’ level of hygiene (34). It is
disturbing to note that in the West the incidence of oral
cancer has recently started to increase, particularly in
young male cohorts who are exposed to traditional risk
factors and low consumption of fruit and vegetables (35).
Tobacco contains several carcinogens and
procarcinogens. The important relevant carcinogens and
procarcinogens in tobacco and alcoholic beverages are
nitrosamines, polycyclic aromatic hydrocarbons,
arylamines, alkyl halides, ethanol and urethane (36).
Dependence on or addiction to nicotine, which is a tertiary
amine, is the main reason for the continued use of
tobacco products. Tertiary amines and secondary amines
(nornicotine, anabasine and anatabine) react with
nitrosating agents to form stable chemicals known as Nnitrosoamines (37). Over 300 different nitrosamines
have been shown to be carcinogenic in experimental
animals (38). Nitrosation of nicotine with sodium nitrite
gives nornitrosonornicotine (NNN) and 4-(methylnitroamino)-1-(3-pyridyl)-1-butanone (NNK) (39). NNN
and NNK related nitrosamines are known as tobaccospecific nitrosamines.
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Although early studies on the formation of tobaccospecific nitrosamines in tobacco demonstrated that it was
produced during curing, subsequent investigations have
shown that the type of post-harvest processing employed
greatly influences the levels of tobacco-specific
nitrosamines in tobacco (40, 41). The eventual levels of
tobacco-specific nitrosamines can also be influenced by
other factors such as tobacco genotype, soil type, climate,
drying process and length and conditions of storage (4042). These factors may also play a role in the differences
in the development of oral tumours between western and
Indian patients.
Nitrosamines require metabolite activation for binding
to DNA and other cellular macromolecules and αhydroxylation of nitrosamines is believed to be important
in their metabolite activation to intermediates which bind
6
to DNA (38). Of these intermediates, O -methlyguanine,
7-methylguanine
and
O4-methylthymine,
O 6methylguanine has been conclusively shown to cause
miscoding (43), and the resulting point mutations can
lead to oncogene activation (44).
One important point is that the levels of tobaccospecific nitrosamines in tobacco products are notably
higher than those of nitrosamines in cigarette smoke.
Although in one study NNN levels were found to be 140240 ng/cigarette in the smoke of a non-filter cigarette,
high levels of NNN were determined in unburned tobacco
such as 0.3-9.0 ppm in cigarette tobacco, 3.0-45.5 ppm
in cigar tobacco, 3.5-90.6 ppm in chewing tobacco and
12.1-29.1 ppm in snuff (37). These levels are among the
highest for environmental nitrosamine in terms of
occurrence and human exposure. However, studies of
NNN concentrations in mainstream and sidestream
tobacco smoke found 0.066-1.01 µg/cigarette and 0.190.86 µg/cigarette respectively (27, 45). Another factor in
exposure to TSNA is in-vivo formation of NNN in the use
of tobacco products. When chewing tobacco was
incubated with human saliva for 3 h at 37°C and the
mixture analyzed for NNN, the concentration of NNN
increased by 44% over that in the chewing tobacco,
presumably as a result of further nitrosation (27). This
additional exposure to TSNA in the use of tobacco
products is also important. Three factors have been found

to be significant in explaining the differences in oral
carcinogenesis. These are: in vivo formation of TSNA, the
high concentrations of TSNA and long exposure periods
compared to smoking, which make smokeless tobacco
products prime candidates as a cause of the development
of oral malignancies due to the fact that the oral mucosa
are exposed for a longer period to higher levels of
tobacco carcinogens.
In conclusion, PCR/DNA sequence analysis would
appear to contradict the theory that ras gene codon 12,
13 and 61 alterations play a role in human oral cancers.
The findings suggest that the existence of genes (p53, cmyc,
calcyclin,
p16/CDKN2)
or
mechanisms
(polymorphism in xenobiotic metabolizing enzyme such
as CYP1A1, CYP1A2, CYP2A6, CYP2D6, CYP2E1 or
GSTM1) other than mutations of ras genes might be
responsible for the development of oral tumour.
One may speculate that tobacco-specific nitrosamines
do not reach high enough concentrations to cause ras
gene mutations in tobacco smoking when their
concentrations are compared with those in smokeless
products. The differences in ras oncogene activation
between tobacco smoke and smokeless tobacco products
may also be an important example of chemical
carcinogenesis in terms of carcinogen quantities and
possible response.
Although cessation of tobacco use is the only way to
totally prevent exposure to carcinogenic TSNA, greater
attention should be paid to smokeless tobacco products
(snuff and chewing tobacco) than to tobacco smoke in the
prevention of oral cancer. Alternatively, ways should be
found to reduce nicotine and TSNA levels in tobacco
through the selection of other tobacco species or
modificcation of the fermentation and processing of
tobacco.
Correspondence author:
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